It has been about a month since the last earnings report for Kymera Therapeutics, Inc. (KYMR Quick QuoteKYMR - Free Report) . Shares have added about 10.2% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Kymera Therapeutics due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Kymera Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late.

Q3 Loss Wider Than Expected, Pipeline Progress Encouraging

Kymera reported a third-quarter 2025 loss of 90 cents per share, wider than the Zacks Consensus Estimate of a loss of 71 cents. In the year-ago quarter, Kymera reported a loss of 82 cents per share. The year-over-year deterioration was due to higher R&D expenses and lower collaboration revenues.

Collaboration revenues totaled $3 million, which missed the Zacks Consensus Estimate of $27 million. Collaboration revenues recognized in the reported quarter were attributable to the company’s collaboration with Gilead Sciences.

In the year-ago quarter, the company earned $3.7 million of collaboration revenues under its association with the pharma bigwig Sanofi.

Operating Expenses Increase in Q3

Research and development expenses totaled $74.1 million, up 22.6% year over year. This was primarily due to increased expenses related to investments in the STAT6 program, platform, and discovery programs, as well as costs associated with continued growth in the research and development organization.

General and administrative expenses totaled $17.3 million, up from $15.5 million in the year-ago quarter due to an increase in legal and professional service fees in support of the company’s growth and an increase in personnel, facility, and other expenses to support its growth as a public company.

As of Sept. 30, 2025, Kymera had $978.7 million in cash, cash equivalents and investments. The company expects that its cash balance will provide a cash runway into the second half of 2028, beyond multiple clinical inflection points in its pipeline.


 

How Have Estimates Been Moving Since Then?

Since the earnings release, investors have witnessed a upward trend in estimates review.

The consensus estimate has shifted 6.52% due to these changes.

VGM Scores

At this time, Kymera Therapeutics has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. Charting a somewhat similar path, the stock was allocated a score of F on the value side, putting it in the fifth quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Kymera Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

Kymera Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Illumina (ILMN Quick QuoteILMN - Free Report) , has gained 4.5% over the past month. More than a month has passed since the company reported results for the quarter ended September 2025.

Illumina reported revenues of $1.08 billion in the last reported quarter, representing a year-over-year change of +0.4%. EPS of $1.34 for the same period compares with $1.14 a year ago.

Illumina is expected to post earnings of $1.22 per share for the current quarter, representing a year-over-year change of +41.9%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.5%.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #1 (Strong Buy) for Illumina. Also, the stock has a VGM Score of C.